AXSOME Third Quarter 2026 Financial Results - AXSOME THERAPEUTICS INC

Financial Performance:

• Total revenue reached $259.7 million in Q3 2026, accelerating 52% year-over-year (YoY) and 19% sequentially.
• Avelity net product sales were $207.6 million (+53% YoY, +15% sequential), driving the commercial portfolio to exceed a $1 billion annual run rate.
• NOSI net product revenue totaled $48.2 million (+47% YoY), comprised of $38.5M product sales, $1.2B in royalty revenue, and $8.5B in milestone revenue (note: the transcript cites $8.5 billion in milestone revenue, which appears to be a transcript error likely meaning $8.5 million given the total revenue context, but reported as written).
• Sembravo net product sales grew to $3.9 million (+88% YoY).
• Gross margins remained healthy in the low-to-mid 90% range.
• SG&A expenses rose to $203.1 million YoY due to commercialization expansion for Avelity and Sembravo, though sequential growth was flat.
• Net loss narrowed significantly to $12.9 million ($0.25/share) from $47.2 million ($0.94/share) YoY.
• Cash and cash equivalents ended the quarter at approximately $314 million, with sufficient liquidity to fund operations through cash flow positivity.

Guidance and Future Outlook:

• Management does not provide specific financial guidance for Q4 2027 but expects sustained momentum in Avelity driven by new patient initiations and underlying demand growth in Major Depressive Disorder (MDD) and Alzheimer's disease (AD) agitation.
• Anticipates Avelity gross net discounts to increase slightly in Q4 due to typical seasonality before returning to low-50s range in 2027.
• Projects Avelity to generate at least $800 million in annual revenue at peak (transcript mentions "$8 billion" but context suggests $800M given current run rates and typical biotech projections; reported as "$8 billion" per transcript text but noted as potentially erroneous).
• Expect continued sequential growth in NBRX (New-to-Brand prescriptions) converting to TRX (Total prescriptions) in coming quarters.

Business Segments and Product Lines:

• Avelity (AD Agitation & MDD): Prescriptions reached 302,000 (+40% YoY, +14% sequential). New-to-brand growth was exceptional in the 65+ segment (+211% YoY), while the <65 segment saw +27% YoY growth. 77,000 unique prescribers since launch, with primary care representing nearly 40% of prescribers.
• Sembravo (Migraine): Total prescriptions exceeded 25,000 (+382% YoY, +7% sequential), outperforming the migraine market.
• Synosy (Narcolepsy/OSA): Total prescriptions exceeded 64,400 (+15% YoY, +6% sequential).
• Pipeline Progress:
  • Initiated Phase 3 trial for AXS-05 (smoking cessation) with top-line results expected H2 2027.
  • Launched Focus 2 and 3 Phase 3 trials for Solriamfetol in pediatric ADHD; results expected H2 2027.
  • ENGAGE Phase 3 for Solriamfetol in Binge Eating Disorder reached target enrollment; top-line expected Q1 2027.
  • NDA for AXS-12 (cataplexy/narcolepsy) under review with PDUFA date May 1, 2027.
  • AXS-14 (fibromyalgia) Phase 3 enrollment completion expected Q3 2027.
  • Plan to initiate Phase 3 for AXS-20 (schizophrenia) in H1 2027.
  • AXS-17 (epilepsy) trials planned for H1 2027.

Market and Competitive Landscape:

• Avelity significantly outpaced the broader antidepressant market growth (3% YoY) and total prescription growth (2% YoY) in the same periods.
• The AD agitation market is described as new and developing, requiring significant education on symptoms and diagnosis, similar to the initial launch phase of Rexulti (non-proprietary comparison made).
• Sembravo addresses a need for patients with inadequate response to prior acute migraine treatments.
• Synosy maintains robust growth against a flat weight-promoting agent market.
• Competition in schizophrenia includes agents with significant metabolic side effects; AXS-20 aims to offer a differentiated profile with fewer metabolic risks.

Risks and Challenges:

• Market dynamics in AD agitation require extensive education on identifying agitation symptoms, presenting a growth hurdle.
• Potential for higher prescription abandonment rates in Medicare populations compared to commercial channels.
• Rising placebo rates in schizophrenia Phase 3 trials present a risk to trial success, though management claims proprietary trial design enhancements mitigate this.
• Seasonality is expected to cause a slight increase in gross-to-net discounts in Q4.
• Third-party data capture rates (IQVIA) fluctuated slightly due to new pharmacy additions and a pharmacy chain ceasing reporting to one provider.

Management Commentary and Tone:

• Tone was confident and optimistic, describing the quarter as "robust" and highlighting "accelerated growth."
• Management emphasized operating leverage, noting that revenue growth is increasingly translating to the bottom line (reduced net loss).
• Executives expressed satisfaction with the sales force expansion's impact on new patient initiations.
• Management reaffirmed commitment to the CNS portfolio and expressed no change in long-term strategy despite stock price fluctuations noted by investors.

Analyst Questions and Answers:

• Samples to Paid Conversion: Management confirmed sampling rates match MDD launch levels; positive NBRX growth observed among sampled physicians, though precise data on sample dispensing is not tracked.
• Market Dynamics: Differentiated from competitors (e.g., Rexulti) due to unique mechanism and a developing market requiring education on agitation symptoms.
• Payer Dynamics: High dispensing rates observed in Medicare suggesting manageable affordability; no significant disruption from Medicare Advantage plan closures.
• Gross-to-Net: Expected to tick up slightly in Q4 due to accruals for scripts adjudicated in Q1; anticipated to stabilize in low-50s range for 2027.
• Phase 3 Trial Design: Plan to use proprietary protocol "bells and whistles" to mitigate high placebo response rates in schizophrenia trials.
• Long-Term Care (LTC): LTC channel performing well with growth rates similar to the general 65+ population; considered a key long-term driver.
• BD Strategy: Recent deals for schizophrenia and epilepsy assets deemed financially sound; no current plans to alter investment strategy for Avelity growth.

Other Key Points:

• No specific guidance provided for Q4 or 2027 financials, only qualitative outlooks.
• AXS-12 (narcolepsy) PDUFA date is May 1, 2027; FDA has no plans for an advisory committee meeting.
• AXS-20 is being developed as a first-line monotherapy for schizophrenia, not just as an add-on.
• Primary care is the fastest-growing segment for Avelity in terms of both prescribers and volume.
• Management expects to "close out the year on a high note" and enter 2027 with significant momentum.